This was lower than the %CV value (< 27%) reported by Uemura et al. [64] and Monnier et al. [26] to help maintain a minimal risk of hypoglycemia in patients with T2D treated with either insulin and/or noninsulin glucose-lowering agents. This evidence concerns the gene INS and type 2 diabetes mellitus.